O******e
发帖数: 4845 | 1 NATURE BIOTECHNOLOGY | NEWS
China's $300 billion goal
Heiko Yang
Nature Biotechnology 29, 779 (2011) doi:10.1038/nbt0911-779b
Published online 08 September 2011
China's central government will spend 10 billion yuan ($1.6 billion) and
raise an additional 30 billion yuan ($4.8 billion) from provincial
governments to gain a leading position in global biopharma. This strategic
investment is part of its Five-Year Plan, aimed at shedding the nation's
reputation as a cheap producer of low-quality products. Of the seven
industries selected for investment, biotech is one of them. "The government
is pouring money to really support innovative work," says Dan Zhang, CEO of
Fountain Medical Development in Beijing, who is reviewing grant proposals
for the Ministry of Science and Technology (MOST). "Almost all of the grant
money will go to preclinical and clinical studies of truly innovative
projects." MOST vice-chairman Liu Yanhua announced at a bioeconomy meeting
in Tianjin in June that the government hopes biotech revenue will exceed 2
trillion yuan ($311 billion) by 2020. Many Western biotechs view China's
commitment to innovation as a boon for both sides, as analysts predict that
partnerships between China and the West will flourish over the next decade.
Whether China's expectations for a meteoric rise will threaten the West's
biotech leadership is uncertain. Ingrid Yin, senior analyst for Oppenheimer
in New York, believes China must first expand its research infrastructure
and attract a talent base before it can develop into a world power in
biotech. "It will be a gradual process," she says. | m*****n
发帖数: 421 | 2 瞧瞧晓东哥的高端创业
BeiGene is a Beijing-based biotech startup that focuses on oncology drugs.
The company has attracted a large investment from pharma giant Merck, along
with an agreement that should allow BeiGene to raise money from other
pharmas and investors as well.
Pfizer is also active in the China market, committing to purchase a $50
million stake in Shanghai Pharmaceutical's upcoming Hong Kong IPO. Pfizer is
one of four companies to participate in the offering which is expected to
raise up to $2.2 billion. | j*****d
发帖数: 787 | 3 1.6b +4.8 b to generate 300 b.
【在 O******e 的大作中提到】
: NATURE BIOTECHNOLOGY | NEWS
: China's $300 billion goal
: Heiko Yang
: Nature Biotechnology 29, 779 (2011) doi:10.1038/nbt0911-779b
: Published online 08 September 2011
: China's central government will spend 10 billion yuan ($1.6 billion) and
: raise an additional 30 billion yuan ($4.8 billion) from provincial
: governments to gain a leading position in global biopharma. This strategic
: investment is part of its Five-Year Plan, aimed at shedding the nation's
: reputation as a cheap producer of low-quality products. Of the seven
|
|
